Literature DB >> 1159496

Significance of absent or faint kidney sign on bone scan.

W M Sy, D Patel, H Faunce.   

Abstract

Seven men, six suffering from widespread bone metastases of prostatic origin and one with urinary bladder carcinoma, demonstrated minimal or no discernible radioactivity in the kidneys and urinary bladder at the time of bone scanning using 99mTc-stannous polyphosphate. The mechanism behind this scan finding is thought to be rapid and enhanced uptake of the radiopharmaceutical by pathologic bone. The significance of the faint or absent kidney sign in bone scanning, particularly in cases where abnormally homogeneous and symmetric radioactivity exists, is discussed.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1159496

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  13 in total

1.  Absent kidney sign associated with symmetrical and uniformly increased uptake of radiopharmaceutical by the skeleton.

Authors:  I Fogelman; J H McKillop; I T Boyle; W R Greig
Journal:  Eur J Nucl Med       Date:  1977-12-30

2.  Abnormally high diffuse activity on bone scintigram. The importance of exposure time for its recognition.

Authors:  T Fukuda; Y Inoue; H Ochi; H Nakazima; H Sawa; Y Onoyama
Journal:  Eur J Nucl Med       Date:  1982

3.  Serial radionuclide imaging during treatment of patients with diffuse bone metastases from carcinoma of the prostate.

Authors:  A C Perkins; J G Hardy; M L Wastie; K M Clifford
Journal:  Eur J Nucl Med       Date:  1982

4.  The "super" bone scan.

Authors:  E A Higginbotham
Journal:  J Natl Med Assoc       Date:  1980-03       Impact factor: 1.798

5.  Metabolic super scan in F-FDG PET/CT imaging.

Authors:  Dae-Weung Kim; Chang Guhn Kim; Soon-Ah Park; Sang-Ah Jung; Sei-Hoon Yang
Journal:  J Korean Med Sci       Date:  2010-07-21       Impact factor: 2.153

6.  Accumulation of 99mTc-HM-PAO in photon deficient areas in bone scan of bone metastasis from hepatocellular carcinoma.

Authors:  N Otsuka; M Fukunaga; K Morita; S Ono; K Nagai; T Tomomitsu; S Yanagimoto; H Mimura; S Yamamoto; Y Hirano
Journal:  Ann Nucl Med       Date:  1992-11       Impact factor: 2.668

7.  Bone marrow scintigraphy in the diagnosis of bone metastasis in prostate cancer.

Authors:  H Fuse; O Nagakawa; H Seto; T Katayama
Journal:  Int Urol Nephrol       Date:  1994       Impact factor: 2.370

8.  Hypocalcemia in patients with prostate cancer.

Authors:  S C Kukreja; A Shanmugam; T E Lad
Journal:  Calcif Tissue Int       Date:  1988-12       Impact factor: 4.333

9.  The usefulness of bone-marrow scintigraphy in the detection of bone metastasis from prostatic cancer.

Authors:  N Otsuka; M Fukunaga; T Sone; M Yoneda; N Saito; H Tanaka; T Tomomitsu; S Yanagimoto; A Muranaka; R Morita
Journal:  Eur J Nucl Med       Date:  1985

10.  F-18 fluorodeoxyglucose positron emission tomography "super scan" in a patient of metastatic primitive neuroectodermal tumor of the kidney.

Authors:  Gaurav Malhotra; Archana Swami; Pinky Shah; Neha Mittal; Sunny J Gandhi; Bp Tiwari; Praful V Jatale; Ramesh V Asopa
Journal:  Indian J Nucl Med       Date:  2012-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.